Results 111 to 120 of about 73,124 (298)

Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?

open access: yes, 2014
Steven D Nathan, Christopher S King Advanced Lung Disease Clinic, Inova Fairfax Hospital, Falls Church, VA, USA Abstract: Idiopathic pulmonary fibrosis (IPF) is a disease that carries a high mortality.
King CS, Nathan SD
core  

A case report: Diagnosis and treatment of idiopathic hypertrophic pachymeningitis

open access: yesIbrain, Volume 11, Issue 1, Page 112-116, Spring 2025.
We reported a case of idiopathic hypertrophic dura meningitis diagnosed in our hospital. The patient repeatedly suffered from headaches, followed by blurred vision in the right eye. During this period, multiple sclerosis was considered for diagnosis, and it improved after hormone treatment.
Zhong Luo   +7 more
wiley   +1 more source

Fatty acid synthase inhibition alleviates lung fibrosis via β-catenin signal in fibroblasts

open access: yesLife Science Alliance
Idiopathic pulmonary fibrosis (IPF) is a fatal disease marked by activated fibroblasts. This study shows fatty acid synthase (FASN) inhibition induces quiescent fibroblasts, reduces β-catenin, and alleviates pulmonary fibrosis, suggesting FASN as a ...
Hui Lian   +13 more
doaj   +1 more source

Update on therapeutic management of idiopathic pulmonary fibrosis

open access: yes, 2015
Argyris Tzouvelekis,1 Francesco Bonella,2 Paolo Spagnolo31Department of Internal Medicine, Section of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA; 2Interstitial and Rare Lung Disease Unit, Ruhrlandklinik ...
Tzouvelekis A, Bonella F, Spagnolo P
core  

Nerandomilast and the Evolving Therapeutic Paradigm in Pulmonary Fibrosis: From Mechanism to Clinical Efficacy

open access: yesiNew Medicine, EarlyView.
Therapeutic mechanism, clinical efficacy and future directions for nerandomilast in pulmonary fibrosis. ABSTRACT The recent Phase III FIBRONEER trials establish nerandomilast, a novel oral phosphodiesterase 4B (PDE4B) inhibitor, as an effective therapy for idiopathic and progressive pulmonary fibrosis. By elevating cyclic adenosine monophosphate (cAMP),
Qianwen Bai   +4 more
wiley   +1 more source

Rapidly Progressive Pulmonary Fibrosis in a Patient Treated with Danazol for Idiopathic Thrombocytopenic Purpura

open access: yesCanadian Respiratory Journal, 2004
The case of a patient that developed pulmonary fibrosis two months after initiation of danazol for treatment of idiopathic thrombocytopenic purpura is described.
Smita Pakhale   +3 more
doaj   +1 more source

Severity of lung injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin E-2 production

open access: yes, 2004
Levels of prostaglandin E-2 (PGE(2)), a potent inhibitor of fibroblast function, are decreased in the lungs of patients with pulmonary fibrosis, which has been shown to be because of limited expression of cyclooxygenase-2 (COX-2).
McAnulty, R J   +35 more
core   +1 more source

Comparison of Retrospective Motion Compensation Techniques for Pulmonary Dynamic Ultrashort Time to Echo MRI in Suspected Idiopathic Pulmonary Fibrosis

open access: yesJournal of Magnetic Resonance Imaging, EarlyView.
ABSTRACT Background Motion can degrade image quality during Ultrashort Time‐to‐Echo (UTE) pulmonary MRI and is particularly prevalent in patients with lung disease. Comprehensive assessment of the impact of motion compensation techniques on image quality and clinical interpretation is needed.
Abhilash S. Kizhakke Puliyakote   +9 more
wiley   +1 more source

Longitudinal 1H and 129Xe Lung MRI in Patients With Post‐COVID Residual Lung Abnormalities

open access: yesJournal of Magnetic Resonance Imaging, EarlyView.
ABSTRACT Background It is unclear how lung function may recover in patients with residual lung abnormalities (RLAs) following COVID‐19 pneumonia. Purpose To evaluate lung function trends over time in patients with RLAs following hospitalization due to COVID‐19. Study Type Prospective, multicenter longitudinal cohort study.
Laura C. Saunders   +41 more
wiley   +1 more source

Telomerase and idiopathic pulmonary fibrosis

open access: yesMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2012
Idiopathic pulmonary fibrosis (IPF) is the most common manifestation of telomere-mediated disorders. Germline mutations in the essential telomerase genes, hTERT and hTR, are the causal genetic defect in up to one-sixth of pulmonary fibrosis families. The presence of telomerase mutations in this subset is significant for clinical decisions as affected ...
openaire   +2 more sources

Home - About - Disclaimer - Privacy